Dr. Adam Wolfberg, Virta Health, on Reversing Type 2 Diabetes and Rethinking GLP-1s

04/07/25 • 45 min

In this episode of The Pulse, I sat down with Dr. Adam Wolfberg, Chief Medical Officer of Virta Health, a company pioneering a new approach to tackling metabolic disease.

Virta Health has a mission to reverse type 2 diabetes and obesity through nutrition-first treatment and tech-enabled care. We discussed Adam’s unconventional journey from news reporter to startup exec, Virta’s science-backed outcomes, and why GLP-1s aren’t the only answer to America’s weight crisis.

In this episode of The Pulse, I sat down with Dr. Adam Wolfberg, Chief Medical Officer of Virta Health, a company pioneering a new approach to tackling metabolic disease.

Previous Episode

Autumn-Kyoko Cushman, ShiftRx, on transforming healthcare staffing

In this episode, I sat down with Autumn-Kyoko (AK) Cushman, co-founder and CEO of ShiftRx, a platform using generative AI to transform pharmacy staffing. Backed by investors like Work-Bench, Inflect Health, Tau Ventures, and Opal Ventures, ShiftRx is tackling one of healthcare’s biggest challenges - staffing shortages - by empowering providers with more control, flexibility, and financial stability.

AK’s path to founding ShiftRx is anything but conventional - she served as a hospital corpsman in the US Navy, worked in management consulting with the National Cancer Institute, and later joined IBM’s Watson Health. Her firsthand exposure to healthcare’s inefficiencies, combined with her co-founder Leann’s experience as a pharmacy technician, led them to build ShiftRx as a provider-first solution.

AK and I discussed the founding story of ShiftRx, the root causes of provider burnout, and how AI can reshape healthcare staffing.

Next Episode

Dr. James Lu, Helix, on making Genomics the Backbone of Preventive Healthcare

In this episode of The Pulse, I had the opportunity to speak with Dr. James Lu, co-founder and CEO of Helix - a precision medicine company using genomics to power preventive care. With over $270 million raised and partnerships spanning major U.S. health systems, Helix is at the forefront of turning DNA into an actionable health asset.